Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 11/20 | 0.70 |
| ▸ | P2RX3 | P56373 | 6/20 | 0.55 |
| ▸ | MET | P08581 | 1/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30879437 | 1.00 | MKNK1 (0.70) | MKNK1P2RX3METADORA1 | |
| SCHEMBL939632 | 0.94 | MKNK1 (0.62) | MKNK1P2RX3MET | |
| SCHEMBL939832 | 0.92 | MKNK1 (0.60) | MKNK1P2RX3MET | |
| SCHEMBL940729 | 0.91 | MKNK1 (0.59) | MKNK1P2RX3METADORA1 | |
| SCHEMBL24996603 | 0.90 | MKNK1 (0.57) | MKNK1P2RX3MET | |
| SCHEMBL30879369 | 0.88 | MKNK1 (0.66) | MKNK1P2RX3METADORA1 | |
| SCHEMBL24996003 | 0.88 | MKNK1 (0.66) | MKNK1P2RX3METADORA1 | |
| SCHEMBL967213 | 0.86 | RXFP1 (0.66) | MKNK1 | |
| SCHEMBL940518 | 0.83 | MKNK1 (0.48) | MKNK1 | |
| SCHEMBL17296473 | 0.83 | MKNK1 (0.48) | MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240391931-A1 | TRICYCLIC FUSED PYRIMIDINE COMPOUNDS FOR USE AS HER2 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2024-11-28 | — | — | US | disclosed |
| EP-4380941-A1 | TRICYCLIC FUSED PYRIMIDINE COMPOUNDS FOR USE AS HER2 INHIBITORS | Bristol-Myers Squibb Company (US) | 2024-06-12 | — | — | EP | disclosed |
| WO-2024048809-A1 | HETEROARYL DERIVATIVE CONTAINING N, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | 보로노이 주식회사 | 2024-03-07 | — | — | WO | disclosed |
| WO-2023015240-A1 | TRICYCLIC FUSED PYRIMIDINE COMPOUNDS FOR USE AS HER2 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-02-09 | — | — | WO | disclosed |
| WO-2023015240-A1 | TRICYCLIC FUSED PYRIMIDINE COMPOUNDS FOR USE AS HER2 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-02-09 | — | — | WO | disclosed |
| US-10561749-B2 | Nuclear medicine diagnostic imaging agent | KYOTO UNIVERSITY (JP) | 2020-02-18 | — | — | US | disclosed |
| US-20170107229-A1 | SUBSTITUTED TETRAHYDROPYRIDOTHIENOPYRIMIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-04-20 | — | — | US | disclosed |
| US-20170107229-A1 | SUBSTITUTED TETRAHYDROPYRIDOTHIENOPYRIMIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-04-20 | — | — | US | disclosed |
| US-20170107229-A1 | SUBSTITUTED TETRAHYDROPYRIDOTHIENOPYRIMIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-04-20 | — | — | US | disclosed |
| EP-3149004-A1 | SUBSTITUTED TETRAHYDROPYRIDOTHIENOPYRIMIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-04-05 | — | — | EP | disclosed |
| WO-2010054285-A2 | FUSED BICYCLIC AND TRICYCLIC PYRIMIDINE COMPOUNDS AS TYROSINE KINASE INHIBITORS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2010-05-14 | — | — | WO | disclosed |
| WO-2010054285-A2 | FUSED BICYCLIC AND TRICYCLIC PYRIMIDINE COMPOUNDS AS TYROSINE KINASE INHIBITORS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2010-05-14 | — | — | WO | disclosed |
| US-20100120805-A1 | Fused Bicyclic and Tricyclic Pyrimidine Compounds as Tyrosine Kinase Inhibitors | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2010-05-13 | — | — | US | disclosed |
| US-20100120805-A1 | Fused Bicyclic and Tricyclic Pyrimidine Compounds as Tyrosine Kinase Inhibitors | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2010-05-13 | — | — | US | disclosed |
| US-20100120805-A1 | Fused Bicyclic and Tricyclic Pyrimidine Compounds as Tyrosine Kinase Inhibitors | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2010-05-13 | — | — | US | disclosed |
| WO-2009033581-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-03-19 | — | — | WO | disclosed |
| WO-2009033581-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-03-19 | — | — | WO | disclosed |
| EP-2001890-A2 | TETRAHYDROPYRIDOTHIENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | Bayer HealthCare AG (DE) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007109279-A2 | TETRAHYDROPYRIDOTHIENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | BAYER HEALTHCARE AG (DE) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007109279-A2 | TETRAHYDROPYRIDOTHIENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | BAYER HEALTHCARE AG (DE) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240391931-A1 | TRICYCLIC FUSED PYRIMIDINE COMPOUNDS FOR USE AS HER2 INHIBITORS | ERBB2, ERBB3, EGFR | MKNK1 671/4885P2RX3 509/4885MET 293/4885 |
| US-20170107229-A1 | SUBSTITUTED TETRAHYDROPYRIDOTHIENOPYRIMIDINES | TYMP, DPYD, TYMS | MKNK1 2433/4885P2RX3 1911/4885MET 1104/4885 |
| US-10561749-B2 | Nuclear medicine diagnostic imaging agent | EGFR, FGFR1, ERBB2 | MKNK1 2276/4885P2RX3 4231/4885MET 5/4885 |
| US-20100120805-A1 | Fused Bicyclic and Tricyclic Pyrimidine Compounds as Tyrosine Kinase Inhibitors | ERBB2, EGFR, BMX | MKNK1 206/4885P2RX3 1763/4885MET 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.